Andrea Demeco, Alessandro de Sire, Antonello Salerno, Nicola Marotta, Beatrice Comuni, Matteo Gabbi, Lorenzo Lippi, Marco Invernizzi, Antonio Ammendolia, Cosimo Costantino
{"title":"自体肌腱细胞注射对过度使用和退行性肌腱病的影响:系统综述。","authors":"Andrea Demeco, Alessandro de Sire, Antonello Salerno, Nicola Marotta, Beatrice Comuni, Matteo Gabbi, Lorenzo Lippi, Marco Invernizzi, Antonio Ammendolia, Cosimo Costantino","doi":"10.3390/jfmk10010095","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> The term tendinopathy commonly describes a series of alterations in the tendon, leading in functional impairment and pain, treated with several approaches, including exercises, physical agents, and injection therapies. Among the latter, autologous tenocyte injection (ATI) involves harvesting tenocytes from a healthy tendon of the patients and then isolating the tenocytes and culturing for 4-5 weeks. To date, there is still a lack of consensus about the efficacy of ATI in improving pain and function; therefore, the present review aimed to assess the role of ATI in the treatment of chronic tendinopathies. <b>Methods:</b> Two authors conducted a comprehensive search across PubMed Medline, Web of Science, Scopus, Cochrane Library, and Google Scholar (PROSPERO: CRD42024565211). From 174 articles, we finally included 5 articles. <b>Results:</b> The main effect obtained was the pain relief and, consequently, the improvement of patients' quality of life. The clinical improvement is also evident at MRI in which it is possible to see a progressive reduction with a general disappearance of the T2 signal hyperintensity between 4 months and 1 year. All the articles agree on the safety of ATI in chronic tendinopathies. <b>Conclusions:</b> ATI might represent a safe and valuable option in the management of chronic tendinopathies as a second line treatment in the case of resistant tendinopathies, with a minimal risk of side effects.</p>","PeriodicalId":16052,"journal":{"name":"Journal of Functional Morphology and Kinesiology","volume":"10 1","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11942842/pdf/","citationCount":"0","resultStr":"{\"title\":\"Effects of Autologous Tenocyte Injection for Overuse and Degenerative Tendinopathies: A Systematic Review.\",\"authors\":\"Andrea Demeco, Alessandro de Sire, Antonello Salerno, Nicola Marotta, Beatrice Comuni, Matteo Gabbi, Lorenzo Lippi, Marco Invernizzi, Antonio Ammendolia, Cosimo Costantino\",\"doi\":\"10.3390/jfmk10010095\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Background:</b> The term tendinopathy commonly describes a series of alterations in the tendon, leading in functional impairment and pain, treated with several approaches, including exercises, physical agents, and injection therapies. Among the latter, autologous tenocyte injection (ATI) involves harvesting tenocytes from a healthy tendon of the patients and then isolating the tenocytes and culturing for 4-5 weeks. To date, there is still a lack of consensus about the efficacy of ATI in improving pain and function; therefore, the present review aimed to assess the role of ATI in the treatment of chronic tendinopathies. <b>Methods:</b> Two authors conducted a comprehensive search across PubMed Medline, Web of Science, Scopus, Cochrane Library, and Google Scholar (PROSPERO: CRD42024565211). From 174 articles, we finally included 5 articles. <b>Results:</b> The main effect obtained was the pain relief and, consequently, the improvement of patients' quality of life. The clinical improvement is also evident at MRI in which it is possible to see a progressive reduction with a general disappearance of the T2 signal hyperintensity between 4 months and 1 year. All the articles agree on the safety of ATI in chronic tendinopathies. <b>Conclusions:</b> ATI might represent a safe and valuable option in the management of chronic tendinopathies as a second line treatment in the case of resistant tendinopathies, with a minimal risk of side effects.</p>\",\"PeriodicalId\":16052,\"journal\":{\"name\":\"Journal of Functional Morphology and Kinesiology\",\"volume\":\"10 1\",\"pages\":\"\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2025-03-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11942842/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Functional Morphology and Kinesiology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3390/jfmk10010095\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"SPORT SCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Functional Morphology and Kinesiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/jfmk10010095","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"SPORT SCIENCES","Score":null,"Total":0}
引用次数: 0
摘要
背景:术语肌腱病变通常描述一系列肌腱改变,导致功能损伤和疼痛,可通过多种方法治疗,包括锻炼、物理药物和注射疗法。在后者中,自体肌腱细胞注射(ATI)涉及从患者的健康肌腱中收集肌腱细胞,然后分离肌腱细胞并培养4-5周。迄今为止,关于ATI在改善疼痛和功能方面的功效仍缺乏共识;因此,本综述旨在评估ATI在慢性肌腱病治疗中的作用。方法:两位作者在PubMed Medline、Web of Science、Scopus、Cochrane Library和b谷歌Scholar (PROSPERO: CRD42024565211)上进行了综合检索。从174篇文章中,我们最终纳入了5篇文章。结果:主要疗效为缓解疼痛,改善患者生活质量。临床改善在MRI上也很明显,在4个月至1年间,可以看到T2信号高强度的逐渐减少和普遍消失。所有的文章都同意ATI治疗慢性肌腱病变的安全性。结论:ATI可能是治疗慢性肌腱病的一种安全而有价值的选择,在耐药肌腱病的情况下作为二线治疗,副作用风险最小。
Effects of Autologous Tenocyte Injection for Overuse and Degenerative Tendinopathies: A Systematic Review.
Background: The term tendinopathy commonly describes a series of alterations in the tendon, leading in functional impairment and pain, treated with several approaches, including exercises, physical agents, and injection therapies. Among the latter, autologous tenocyte injection (ATI) involves harvesting tenocytes from a healthy tendon of the patients and then isolating the tenocytes and culturing for 4-5 weeks. To date, there is still a lack of consensus about the efficacy of ATI in improving pain and function; therefore, the present review aimed to assess the role of ATI in the treatment of chronic tendinopathies. Methods: Two authors conducted a comprehensive search across PubMed Medline, Web of Science, Scopus, Cochrane Library, and Google Scholar (PROSPERO: CRD42024565211). From 174 articles, we finally included 5 articles. Results: The main effect obtained was the pain relief and, consequently, the improvement of patients' quality of life. The clinical improvement is also evident at MRI in which it is possible to see a progressive reduction with a general disappearance of the T2 signal hyperintensity between 4 months and 1 year. All the articles agree on the safety of ATI in chronic tendinopathies. Conclusions: ATI might represent a safe and valuable option in the management of chronic tendinopathies as a second line treatment in the case of resistant tendinopathies, with a minimal risk of side effects.